31/07/2018

ESTEVE’S RDI, AGAIN RATED ’EXCELLENT’ BY THE PROFARMA PLAN

The Profarma Plan (Plan for the Promotion of Scientific Research, Development and Technological Innovation in the Pharmaceutical Industry), a joint program of the Ministry of Industry, Energy and Tourism and of the Ministry of Health, Social Services and Equality, has again rated ESTEVE’s RDI as 'excellent'

This rating acknowledges the company’s commitment to innovation, with an important part of its workforce devoted to top-level research. Over the last year, ESTEVE has invested more than 81 million Euros in R&D.

ESTEVE appears in Group A of the Profarma Plan (2017-2020), which includes companies that conduct significant research activities and have their own center of production or basic or preclinical R&D.

The main purpose of the Profarma Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector, strengthening the activities that provide the highest added value, and fostering research, development and innovation.

Last news

  • ESTEVE ANNOUNCES A RESTRUCTURING OF ITS PHARMACEUTICAL ACTIVITY

    Esteve Pharmaceuticals submits a reduction in force (RIF) which will affect 103 jobs in Spain

    read more
  • NURSES OFFER CARE AND PREVENTION OF DRY EYE, A CONDITION THAT AFFECTS 60% OF PEOPLE OLDER THAN 45 YEARS

    Dry eye care and prevention is a pending issue in the Spanish society and a source of great concern for specific patients, such as those admitted to Intensive Care Units.

    The longer time...

    read more
  • ONE THIRD OF DIABETIC PATIENTS ARE OLDER THAN 75 YEARS AND THEIR HYPOGLYCEMIA GOES UNDETECTED IN 1 OUT OF 5 CASES

    According to experts attending Diabeclass, a meeting organized by ESTEVE
    at its corporate headquarters titled "Managing elderly patients with
    type 2 diabetes".

    The priority ...

    read more

Follow us at

This Website uses its own and third-party cookies to improve our services and analyse the user's browsing habits. If you continue browsing, we will consider you to have accepted their use. You can find more information by visiting our Cookies policy.